RPL36 Antibody

What is RPL36 and what is its role in cellular physiology?

RPL36 (ribosomal protein L36) is a 105 amino acid protein that functions as a component of the large ribosomal subunit (60S). It plays a crucial role in protein synthesis, which drives many cellular processes. As part of the ribosome, RPL36 contributes to the machinery responsible for translating mRNA into proteins . The molecular weight of RPL36 is calculated to be approximately 12 kDa, though in laboratory settings it is typically observed at 12-14 kDa when analyzed by western blotting . RPL36 may be involved in the early stage of hepatocarcinogenesis and has been identified as a potential independent prognostic marker for resected hepatocellular carcinoma (HCC) .

What are the typical applications for RPL36 antibodies in research?

RPL36 antibodies have several validated applications in research settings:

When designing experiments with RPL36 antibodies, researchers should titrate the antibody in each testing system to obtain optimal results, as sample-dependent variations may occur .

In which cell lines and tissues has RPL36 expression been validated?

RPL36 antibodies have demonstrated positive reactivity in multiple cell lines and tissues:

For immunofluorescence applications, HeLa cells have been particularly well-validated for RPL36 detection .

What are the recommended protocols for Western blotting with RPL36 antibodies?

For optimal Western blotting results with RPL36 antibodies:

• Sample preparation: Prepare cell lysates using standard lysis buffers containing protease inhibitors

• Protein separation: Use 12-15% SDS-PAGE gels to effectively resolve the 12-14 kDa RPL36 protein

• Transfer: Employ PVDF or nitrocellulose membranes with standard transfer conditions

• Blocking: Block membranes with 5% non-fat milk or BSA in TBST

• Primary antibody: Dilute RPL36 antibody 1:500-1:2000 in blocking buffer

• Incubation: Overnight at 4°C or 1-2 hours at room temperature

• Detection: Use appropriate HRP-conjugated secondary antibodies and ECL detection systems

Expected band size is 12-14 kDa, which corresponds to the observed molecular weight of RPL36 .

What are the best practices for immunofluorescence staining of RPL36?

For effective immunofluorescence staining of RPL36:

• Cell preparation: Grow cells on coverslips to 60-80% confluency

• Fixation: Fix with 4% paraformaldehyde for 15-20 minutes at room temperature

• Permeabilization: Use 0.1-0.5% Triton X-100 for 5-10 minutes

• Blocking: Block with 1-5% BSA or normal serum for 30-60 minutes

• Primary antibody: Dilute RPL36 antibody 1:50-1:800 in blocking solution

• Incubation: Incubate overnight at 4°C or 1-2 hours at room temperature

• Secondary antibody: Use appropriate fluorophore-conjugated secondary antibodies

• Nuclear counterstain: DAPI is commonly used for nuclear staining

• Mounting: Mount with anti-fade mounting medium

Confocal microscopy is recommended for optimal visualization of RPL36 subcellular localization .

How should RPL36 antibodies be stored and handled for maximum stability?

For optimal storage and stability of RPL36 antibodies:

• Storage temperature: Store at -20°C

• Buffer conditions: Most commercial RPL36 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Stability: Typically stable for one year after shipment when stored properly

• Aliquoting: Aliquoting is generally unnecessary for -20°C storage

• Freeze/thaw cycles: Avoid repeated freeze/thaw cycles to maintain antibody integrity

• Working dilutions: Prepare fresh working dilutions on the day of experiment

Some commercial preparations may contain 0.1% BSA for additional stability .

What is alt-RPL36 and how does it differ from canonical RPL36?

Alt-RPL36 is an alternative protein co-encoded with human RPL36 that has been discovered through molecular and proteomic evidence. Key differences include:

• Reading frame: Alt-RPL36 is translated in the -1 reading frame relative to RPL36

• Sequence: Despite overlapping genomic location, the amino acid sequences of RPL36 and alt-RPL36 are completely different

• Size: Alt-RPL36 is longer than RPL36 and completely encompasses its coding sequence

• Expression: Alt-RPL36 has been detected in multiple human cell lines including HEK 293T, HT1080, and MOLT4 cells

• Localization: Endogenously expressed alt-RPL36 partially localizes to the endoplasmic reticulum, unlike canonical RPL36 which is primarily found in ribosomes

This discovery highlights the complexity of the human proteome and demonstrates how alternative reading frames can generate functionally distinct proteins from the same genomic locus .

How does alt-RPL36 impact cellular signaling pathways?

Alt-RPL36 has been shown to downregulate the PI3K-AKT-mTOR signaling pathway, which is critical for cell growth, proliferation, and survival. Research indicates that:

• Phosphorylated alt-RPL36 interacts with the phospholipid transfer protein TMEM24/C2CD2L

• This interaction occurs via the SMP and C2 domains of TMEM24

• The interaction was confirmed through co-immunoprecipitation experiments and validated by both LC-MS/MS and western blotting

• Alt-RPL36 was identified to partially localize to the endoplasmic reticulum, suggesting potential roles in ER-related functions

These findings suggest that alt-RPL36 may function as a regulatory protein affecting cellular signaling, distinct from the canonical role of RPL36 in ribosome biology .

How can RPL36 antibodies be used to study ribosomal stress responses?

RPL36 antibodies can provide valuable insights into ribosomal stress responses through:

• Quantitative analysis: Western blotting with RPL36 antibodies can measure changes in expression levels during cellular stress

• Localization studies: Immunofluorescence can track changes in subcellular localization of RPL36 during stress responses

• Ribosomal integrity assessment: Changes in RPL36 levels can indicate alterations in 60S ribosomal subunit integrity

• Comparison with SSU components: Paired analysis with small subunit proteins (like RpS12 or RACK1) can reveal differential effects on large versus small ribosomal subunits

• Genetic manipulation contexts: RPL36 antibodies can assess protein levels in cells with mutations in other ribosomal components

Research has shown that cells with mutations in large subunit components (like RpL27A) show reduced levels of LSU proteins, while cells with mutations in small subunit components (RpS17, RpS18) show reduced levels of SSU proteins but normal or slightly elevated levels of LSU proteins like RPL36 .

What is the relationship between RPL36 and HIV-1 infection studies?

The role of RPL36 in HIV-1 infection has been investigated as part of broader studies on host intrinsic factors controlling disease progression. Research findings indicate:

• Differential expression: RPL36 shows altered expression patterns in HIV controllers compared to normal progressors

• Experimental approaches: HIV infection assays using VSV-G pseudotyped HIV-1 reporter viruses have been employed to study the effects of various genes on viral replication

• Protein expression impact: Some ribosomal proteins have been shown to affect HIV-1 Gag expression levels when overexpressed

• Transcriptional profile: RPL36 has been identified in meta-analyses of transcriptional profiles comparing long-term non-progressors or elite controllers with normal HIV progressors

While specific effects of RPL36 on HIV infection haven't been fully characterized, research methodologies used for studying other ribosomal proteins provide a framework for investigating RPL36's potential role in viral infection contexts .

What experimental approaches can be used to study the relationship between RPL36 and cancer?

To investigate RPL36's potential role in cancer, researchers can employ several methodologies:

• Expression analysis: Quantify RPL36 expression levels in tumor versus normal tissue using Western blotting, qPCR, and IHC

• Prognostic correlation: Analyze the relationship between RPL36 expression levels and patient outcomes in hepatocellular carcinoma and other cancers

• Functional studies: Use siRNA or CRISPR-Cas9 to knockdown or knockout RPL36 in cancer cell lines and assess effects on proliferation, invasion, and apoptosis

• Protein interaction studies: Identify cancer-relevant binding partners of RPL36 using co-immunoprecipitation followed by mass spectrometry

• Alternative protein analysis: Investigate the potential role of alt-RPL36 in modulating PI3K-AKT-mTOR signaling, which is frequently dysregulated in cancer

Research has indicated that RPL36 may be involved in the early stage of hepatocarcinogenesis and can potentially serve as an independent prognostic marker for resected HCC .

How can researchers optimize antibody dilutions for different RPL36 detection applications?

To optimize RPL36 antibody dilutions across different applications:

• Initial titration: Perform a dilution series based on the manufacturer's recommended ranges:

  • WB: 1:500, 1:1000, 1:2000

  • IHC: 1:50, 1:100, 1:200

  • IF/ICC: 1:50, 1:200, 1:800

• Sample considerations:

  • Cell type specificity: Different cell lines may require adjusted dilutions

  • Tissue fixation method: Formalin-fixed versus frozen sections may require different antibody concentrations

  • Expression level variations: Cancer versus normal tissues may show different optimal dilutions

• Signal-to-noise optimization:

  • Increase antibody concentration if signal is weak

  • Decrease concentration if background is high

  • Consider longer incubation times at lower concentrations to improve specificity

• Validation controls:

  • Include peptide competition assays to confirm specificity

  • Use positive control samples with known RPL36 expression

  • Include secondary-only controls to assess background

Each testing system requires individual optimization to obtain optimal results .

What are the common challenges in detecting RPL36 and how can they be addressed?

Researchers may encounter several challenges when working with RPL36 antibodies:

• Cross-reactivity with other ribosomal proteins:

  • Solution: Validate antibody specificity using peptide competition assays

  • Solution: Use multiple antibodies targeting different epitopes of RPL36

• Low molecular weight detection issues:

  • Solution: Use higher percentage (15-20%) gels for better resolution of the 12-14 kDa protein

  • Solution: Optimize transfer conditions for small proteins (higher methanol concentration, lower voltage)

• High background in immunofluorescence:

  • Solution: Increase blocking time and concentration

  • Solution: Use specialized blocking reagents like Image-iT FX Signal Enhancer

  • Solution: Optimize primary antibody dilution and incubation time

• Distinguishing between RPL36 and alt-RPL36:

  • Solution: Use epitope-specific antibodies that target unique regions

  • Solution: Perform knockout/knockdown validation to confirm specificity

  • Solution: Use tagged versions for overexpression studies

• Tissue-specific optimization:

  • Solution: Adjust antigen retrieval methods for different tissue types

  • Solution: Optimize fixation protocols for specific applications

Proper controls and method optimization are essential for reliable RPL36 detection across different experimental contexts .